COAG on Nasdaq

Hemab Therapeutics Holdings, Inc.

American biological products company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

TickerCOAG on Nasdaq¹
IndustryBiological Products, (No Diagnostic Substances)¹
HeadquartersCambridge, Massachusetts¹
Incorporated inDE²
Business address101 Main Street, Suite 1220, Cambridge, Ma 02142²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Leadership

Who has led Hemab Therapeutics Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief operating officer

Ananthram Sreenivasa Murthy2026–now

Chief operating officerAnanthram Sreenivasa Murthy Apr 30, 2026 to now³

Board members and other officers (11)

OfficerBenny Sorensen Apr 30, 2026 to now⁴
Chief Medical OfficerCatherine Madigan Apr 30, 2026 to now⁵
OfficerMads Nikolaj Behrndt-Eriksen Apr 30, 2026 to now⁶
Board memberAkshay Vaishnaw Apr 30, 2026 to now⁷
Board memberBenny Sorensen Apr 30, 2026 to now⁴
Board memberJohn Maraganore Apr 30, 2026 to now⁸
Board memberLaura Tadvalkar Apr 30, 2026 to now⁹
Board memberLinda Bain Apr 30, 2026 to now¹⁰
Board memberPeter Kolchinsky Apr 30, 2026 to now¹¹
Board memberRajeev M. Shah Apr 30, 2026 to now¹¹
Board memberKeli Walbert Sep 25, 2026 to now¹²

Filings

50 filings to the SEC since October 2021: 2 quarterly reports, 5 major events, 22 insider forms, 9 large holders, 12 other. The latest 20:

Sep 25, 20264 EDGAR
Sep 25, 20263 EDGAR
Sep 24, 20268-K EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 12, 2026SCHEDULE 13G EDGAR
Aug 11, 202610-Q EDGAR
Aug 11, 20268-K EDGAR
Aug 7, 2026SCHEDULE 13G EDGAR
Aug 6, 2026SCHEDULE 13G EDGAR
Aug 5, 2026SCHEDULE 13G EDGAR
Jun 17, 20264 EDGAR
May 21, 20264 EDGAR
May 21, 202610-Q EDGAR
May 21, 20268-K EDGAR
May 14, 20264 EDGAR
May 14, 20263 EDGAR
May 11, 2026SCHEDULE 13G EDGAR
May 11, 20264 EDGAR
May 11, 2026SCHEDULE 13D EDGAR

The 50 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 11 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Jun 16, 2026	RA CAPITAL MANAGEMENT, L.P.10% owner	Buy	61,523	$24.98	$1.5M	Form 4
Jun 15, 2026	RA CAPITAL MANAGEMENT, L.P.10% owner	Buy	6,146	$24.89	$153.0K	Form 4
May 20, 2026	RA CAPITAL MANAGEMENT, L.P.10% owner	Buy	996	$24.94	$24.8K	Form 4
May 19, 2026	RA CAPITAL MANAGEMENT, L.P.10% owner	Buy	3,802	$24.97	$94.9K	Form 4
May 12, 2026	Kolchinsky Peter10% owner	Buy	6,387	$24.90	$159.0K	Form 4
May 11, 2026	RA Capital Healthcare Fund LP10% owner	Buy	39,869	$24.81	$989.2K	Form 4
May 8, 2026	RA Capital Healthcare Fund LP10% owner	Buy	1,483	$24.98	$37.0K	Form 4
May 7, 2026	RA Capital Healthcare Fund LP10% owner	Buy	9,906	$24.46	$242.3K	Form 4
May 6, 2026	Shah Rajeev M.10% owner	Buy	68,018	$24.60	$1.7M	Form 4
May 5, 2026	Shah Rajeev M.10% owner	Buy	97,411	$24.63	$2.4M	Form 4
May 4, 2026	Shah Rajeev M.10% owner	Buy	2,675,000	$18.00	$48.1M	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Avoro Capital Advisors LLCSCHEDULE 13G, 1 filing Aug 14, 2026¹³
Novo Holdings A/SSCHEDULE 13G, 1 filing Aug 14, 2026¹⁴
Capital International InvestorsSCHEDULE 13G, 1 filing Aug 12, 2026¹⁵
Invus Global Management, LLCSCHEDULE 13G, 1 filing Aug 7, 2026¹⁶
FMR LLCSCHEDULE 13G, 1 filing Aug 6, 2026¹⁷
Sofinnova Crossover II S.L.P.SCHEDULE 13G, 1 filing Aug 5, 2026¹⁸
AI DEN-MAB LLCSCHEDULE 13D, 1 filing May 11, 2026¹⁹
RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G, 1 filing May 11, 2026²⁰
Deep Track Capital, LPSCHEDULE 13G, 1 filing May 8, 2026²¹

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 55. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Ra Capital Management, L.P.	7,808,627	$286.8M	2.5%	New
Novo Holdings A/s	4,180,550	$153.6M	8.9%	New
Fmr LLC	3,697,837	$135.8M	0.0%	New
Capital International Investors	3,603,876	$132.4M	0.0%	New
Deep Track Capital, LP	3,602,093	$132.3M	1.9%	New
Siren, L.L.C.	2,086,834	$76.6M	1.6%	New
Avoro Capital Advisors LLC	1,925,150	$70.7M	0.6%	New
Bain Capital Life Sciences Investors, LLC	1,650,000	$60.6M	3.6%	New
Jpmorgan Chase & Co	1,152,420	$42.3M	0.0%	New
Vanguard Capital Management LLC	780,758	$28.7M	0.0%	New
Driehaus Capital Management LLC	715,791	$26.3M	0.2%	New
Rock Springs Capital Management LP	575,432	$21.1M	1.0%	New
Bellevue Group AG	550,000	$20.2M	0.4%	New
Citadel Advisors LLC	523,450	$19.2M	0.0%	New
BlackRock, Inc.	283,833	$10.4M	0.0%	New
Deerfield Management Company, L.P.	275,000	$10.1M	0.1%	New
ExodusPoint Capital Management, LP	218,287	$8.0M	0.1%	New
Geode Capital Management, LLC	211,798	$7.8M	0.0%	New
Braidwell LP	160,000	$5.9M	0.2%	New
Marshall Wace, Llp	154,674	$5.7M	0.0%	New
Woodline Partners LP	150,040	$5.5M	0.0%	New
Affinity Asset Advisors, LLC	138,030	$5.1M	0.3%	New
Ensign Peak Advisors, Inc	115,394	$4.2M	0.0%	New
Vanguard Fiduciary Trust Co	112,499	$4.1M	0.0%	New
Charles Schwab Investment Management Inc	108,236	$4.0M	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARHemab Therapeutics Holdings, Inc. filings on SEC EDGAR
2
SEC EDGARHemab Therapeutics Holdings, Inc. filings on SEC EDGAR
3
SEC EDGARAnanthram Sreenivasa Murthy, Chief operating officer
4
SEC EDGARBenny Sorensen, Officer
5
SEC EDGARCatherine Madigan, Chief Medical Officer
6
SEC EDGARMads Nikolaj Behrndt-Eriksen, Officer
7
SEC EDGARAkshay Vaishnaw, Board member
8
SEC EDGARJohn Maraganore, Board member
9
SEC EDGARLaura Tadvalkar, Board member
10
SEC EDGARLinda Bain, Board member
11
SEC EDGARPeter Kolchinsky, Board member
12
SEC EDGARKeli Walbert, Board member
13
SEC EDGARAvoro Capital Advisors LLC SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.
14
SEC EDGARNovo Holdings A/S SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.
15
SEC EDGARCapital International Investors SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.
16
SEC EDGARInvus Global Management, LLC SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.
17
SEC EDGARFMR LLC SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.
18
SEC EDGARSofinnova Crossover II S.L.P. SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.
19
SEC EDGARAI DEN-MAB LLC SCHEDULE 13D on Hemab Therapeutics Holdings, Inc.
20
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.
21
SEC EDGARDeep Track Capital, LP SCHEDULE 13G on Hemab Therapeutics Holdings, Inc.